| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5698752 | Clinical Oncology | 2014 | 6 Pages |
Abstract
We have shown that there is no discernible dosimetric advantage to choosing Cyberknife over Rapidarc for SBRT delivery in prostate cancer. Given the significant benefits of Rapidarc in terms of availability, planning and delivery time, the authors suggest that phase III trials of SBRT should include Rapidarc or equivalent rotational delivery platforms.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
N.D. MacDougall, C. Dean, R. Muirhead,